Newsfile Corp
25 Feb 2026, 01:26 UTC · 30w ago
Verdict
Headline takes no side. We score VTGN −1.00 across two claims — strongly bearish.
−1.00strongly bearish
More negative than 95% of ticker scores this week
What the story claims
2 claims · scored −1 bearish … +1 bullish
Vistagen's PALISADE-3 study of fasedienol failed to meet its primary efficacy endpoint for the acute treatment of social anxiety disorder.
So whatClinical trial failure for a lead drug candidate is a catastrophic event for biotech valuations, as evidenced by the 81% stock price collapse.
More negative than 99% of claims this week
A federal securities class action lawsuit has been filed against Vistagen alleging false or misleading statements regarding the likelihood of Phase 3 success.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 3 movers · tap to explore
More negative than 86% of claims this week
Which stocks this story touches
More negative than 95% of ticker scores this week
The company's stock fell over 81% following a failed clinical trial and is facing a securities class action lawsuit for allegedly misleading investors.
More negative than 75% of ticker scores this week
The company is mentioned in the context of a securities class action lawsuit deadline.
More negative than 75% of ticker scores this week
The company is mentioned in the context of a securities class action lawsuit deadline.
More negative than 75% of ticker scores this week
The company is mentioned in the context of a securities class action lawsuit deadline.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
GlobeNewsWire
4h ago
−52.1%
Price agrees with the score
$0.2670 vs $0.5574 close before publication (Feb 24) · not market-adjusted
VTGN chart →
